BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. European Journal of Internal Medicine 2010;21:310-4. [DOI: 10.1016/j.ejim.2010.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP, Pajares JM. Treatment of Helicobacter pylori infection: The past and the future. European Journal of Internal Medicine 2010;21:357-9. [DOI: 10.1016/j.ejim.2010.07.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
2 Ierardi E, Losurdo G, Giorgio F, Iannone A, Principi M, Leo AD. Quinolone-based first, second and third-line therapies for Helicobacter pyloriWorld J Pharmacol 2015; 4(4): 274-280 [DOI: 10.5497/wjp.v4.i4.274] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, Oak JH, Jung SH. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785-90. [PMID: 21655065 DOI: 10.3346/jkms.2011.26.6.785] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
4 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16 Suppl 1:53-58. [PMID: 21896086 DOI: 10.1111/j.1523-5378.2011.00881.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
5 Arj A, Mollaei M, Razavizadeh M, Moraveji A. The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication. J Res Pharm Pract 2020;9:101-5. [PMID: 33102384 DOI: 10.4103/jrpp.JRPP_19_86] [Reference Citation Analysis]
6 Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475. [PMID: 29512258 DOI: 10.1111/hel.12475] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 25.5] [Reference Citation Analysis]
7 Shah A, Javid G, Zargar SA, Teli F, Khan BA, Yattoo GN, Gulzar GM, Sodhi JS, Khan MA, Shoukat A. Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. Indian J Gastroenterol. 2013;32:32-36. [PMID: 23224792 DOI: 10.1007/s12664-012-0285-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
8 Laupland KB, Fisman DN. A new paradigm for clinical trials in antibiotherapy? Can J Infect Dis Med Microbiol 2011;22:39-42. [PMID: 22654923 DOI: 10.1155/2011/412857] [Reference Citation Analysis]
9 Mahmoudi L, Farshad S, Seddigh M, Mahmoudi P, Ejtehadi F, Niknam R. High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy. Medicine (Baltimore). 2016;95:e4410. [PMID: 27759625 DOI: 10.1097/md.0000000000004410] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
10 Alsohaibani F, Al Ashgar H, Al Kahtani K, Kagevi I, Peedikayil M, Alfadda A, Khan M. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015;21:220-5. [PMID: 26228365 DOI: 10.4103/1319-3767.161647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Senatore FJ, Wilmot J, Birk JW. Helicobacter pylori treatment: Still a work in progress. Postgrad Med. 2016;128:152-157. [PMID: 26490697 DOI: 10.1080/00325481.2016.1103194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014;9:e85620. [PMID: 24465624 DOI: 10.1371/journal.pone.0085620] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
14 Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf. 2014;23:443-455. [PMID: 24677603 DOI: 10.1002/pds.3581] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
15 Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96:e5859. [PMID: 28207505 DOI: 10.1097/MD.0000000000005859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
17 Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, Rabkin CS, Gana JC, Cortés P, Herrero R, Durán L, García A, Toledo C, Espino A, Lustig N, Sarfatis A, Figueroa C, Torres J, Riquelme A. Management of Helicobacter pylori infection in Latin America: A Delphi technique-based consensus. World J Gastroenterol 2014; 20(31): 10969-10983 [PMID: 25152601 DOI: 10.3748/wjg.v20.i31.10969] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
18 Alboraie M, Elhossary W, Aly OA, Abbas B, Abdelsalam L, Ghaith D, Shady Z, Gaber Y, Adel E, Peura D, Armstrong D, Esmat G; special interest group., Egyptian Association for Study of Gastrointestinal Diseases and Liver (E A S G L D). Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab J Gastroenterol 2019;20:175-9. [PMID: 31564518 DOI: 10.1016/j.ajg.2019.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.e14. [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006] [Cited by in Crossref: 362] [Cited by in F6Publishing: 311] [Article Influence: 60.3] [Reference Citation Analysis]
20 Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori A systematic review and meta-analysis. Scand J Gastroenterol. 2014;49:528-538. [PMID: 24611790 DOI: 10.3109/00365521.2014.887765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
21 Coelho LG, Maguinilk I, Zaterka S, Parente JM, do Carmo Friche Passos M, Moraes-Filho JP. 3rd Brazilian Consensus on Helicobacter pylori. Arq Gastroenterol. 2013;50. [PMID: 23748591 DOI: 10.1590/s0004-28032013005000001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
22 dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of Helicobacter pylori infection: A review. World J Gastroenterol 2015; 21(1): 139-154 [PMID: 25574087 DOI: 10.3748/wjg.v21.i1.139] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
23 Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of Helicobacter pyloriWorld J Gastroenterol 2014; 20(27): 8947-8956 [PMID: 25083067 DOI: 10.3748/wjg.v20.i27.8947] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 Sun T, Chen ZX, Li P, He XL. Drug resistance of Helicobacter pylori in Zhejiang: Comparison of three methods for detection of drug resistance. Shijie Huaren Xiaohua Zazhi 2018; 26(18): 1111-1118 [DOI: 10.11569/wcjd.v26.i18.1111] [Reference Citation Analysis]